Literature DB >> 1845947

In situ hybridization for the detection of Epstein-Barr virus in central nervous system lymphomas.

R E Nakhleh1, J C Manivel, C M Copenhaver, J H Sung, J G Strickler.   

Abstract

Epstein-Barr virus (EBV) has been implicated in the development of lymphomas in immunocompromised patients. To test this hypothesis, 26 lymphomas involving the central nervous system (CNS) (11 primary, 15 systemic) were studied for the presence of EBV. In situ hybridization (ISH) was performed on formalin-fixed, paraffin-embedded tissue using a sulfur 35 (35S)-labeled EBV probe (EBV BAMH1-W). The results were interpreted without knowledge of the patients' immunologic status. The EBV sequences were detected in 11 lymphomas, nine of which were mixed or large cell subtypes. Review of the clinical information revealed that nine of the 26 lymphomas occurred in immunocompromised patients secondary to renal transplantation, human immunodeficiency virus infection, leukemia, and Wiskott-Aldrich syndrome. The EBV sequences were detected in all nine lymphomas occurring in immunocompromised patients, whereas two of the 17 lymphomas occurring in immunocompetent patients expressed EBV sequences. The authors conclude that the presence of EBV sequences in CNS lymphomas is highly correlated with a history of compromised immune status supporting a pathogenetic role of EBV in the development of CNS lymphomas in immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845947     DOI: 10.1002/1097-0142(19910115)67:2<444::aid-cncr2820670221>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Epstein-Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing.

Authors:  Yasuo Sugita; Mizuhiko Terasaki; Daisuke Niino; Koichi Ohshima; Arakawa Fumiko; Minoru Shigemori; Yasuharu Sato; Naoko Asano
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

2.  Epstein-Barr and human immunodeficiency viruses in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Authors:  S Morgello
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

Review 3.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Epstein-Barr virus and brain lymphomas.

Authors:  R M Bashir; F H Hochberg; M X Wei
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

5.  Detection of Eber-1 RNA in primary brain lymphomas in immunocompetent and immunocompromised patients.

Authors:  R Bashir; B McManus; C Cunningham; D Weisenburger; F Hochberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 6.  Primary central nervous system lymphomas--an update.

Authors:  K A Jellinger; W Paulus
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

7.  Primary cerebral lymphoma: a study of 47 cases probed for Epstein-Barr virus genome.

Authors:  J F Geddes; M B Bhattacharjee; K Savage; F Scaravilli; J E McLaughlin
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

8.  Three cases of primary cerebral lymphoma in AIDS patients: detection of Epstein-Barr virus by in situ hybridization and Southern blot technique.

Authors:  C Vital; J P Merlio; J Rivel; A Vital; P Gautris; M Beylot; A de Mascarel; B Bloch
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

9.  A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas.

Authors:  S J Hamilton-Dutoit; G Pallesen
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.